We owe it
to our communities.

RARE - Daniela Malik

In the latest episode of Rare, we had the pleasure of speaking with Daniela Malik, an accomplished marketing director with extensive experience in developing and delivering integrated marketing, brand, and communication strategies for multinational corporations within the life sciences sector.

RARE - Tom Pulles

For this episode of RARE I had the pleasure of speaking with Tom Pulles. Tom is a strategic, high-performance medical leader within the Biopharmaceutical environment with experience in Global & Regional Medical Affairs & Strategy, Medical Education, Evidence Generation, Patient Advocacy & Engagement, of which more than a decade in Rare Diseases. 

Digital Health Digest | Meri Beckwith

In this interview, Ellis is joined by Meri Beckwith, co-founder of Lindus Health. They discuss the most common misconceptions when considering clinical trials for digital health solutions, why digital health companies should conduct clinical trials and the post-clinical trial process. They also delved into the increase in poly-indication digital health solutions and how this is currently impacting the digital health industry. 

RARE - Michal Konstacky

For this episode of RARE, I had the pleasure of speaking with Michal Konstacky to expand further on the topic of the increasing use of AI within healthcare.

SciPro announces the release of their biotech and pharma salary survey 2024

SciPro has released their downloadable Salary Survey. Drawing upon the invaluable input from industry leaders, SciPro’s survey focused on the US biotech and pharma market by gathering data from over 500 biotech and pharma professionals from across the US, meticulously sourced from our professional network.

What will Brexit mean for the UK Pharma-industry? 

The referendum is being watched closely by many leading players in the pharmaceutical industry who argue that a Brexit vote would be damaging for research and patient access. 

I cannot be what I cannot see 

DTx Spotlight: An interview with Acacia Parks 

In this episode of DTx Spotlight, Acacia Parks, a digital health executive, discusses the importance of sham comparator studies in digital therapeutics (DTx). She highlights their role in meeting FDA requirements and enhancing research within the industry. Acacia provides insights into why DTx companies should consider conducting these studies and offers guidance on their development. Learn how sham comparator studies are shaping the future of DTx during this insightful interview.